128 related articles for article (PubMed ID: 21072815)
21. Oral iron chelators and the treatment of iron overload in pediatric patients with chronic anemia.
Vichinsky E
Pediatrics; 2008 Jun; 121(6):1253-6. PubMed ID: 18519495
[No Abstract] [Full Text] [Related]
22. Risk factors for hyperferritinemia secondary to red blood cell transfusions in pediatric cancer patients.
Amid A; Barrowman N; Vijenthira A; Lesser P; Mandel K; Ramphal R
Pediatr Blood Cancer; 2013 Oct; 60(10):1671-5. PubMed ID: 23776184
[TBL] [Abstract][Full Text] [Related]
23. Autografting as a risk factor for persisting iron overload in long-term survivors of acute myeloid leukaemia.
Butt NM; Clark RE
Bone Marrow Transplant; 2003 Nov; 32(9):909-13. PubMed ID: 14561992
[TBL] [Abstract][Full Text] [Related]
24. Is the number of blood products transfused associated with lower survival in children with acute lymphoblastic leukemia?
Jaime-Pérez JC; Colunga-Pedraza PR; Gómez-Almaguer D
Pediatr Blood Cancer; 2011 Aug; 57(2):217-23. PubMed ID: 21671359
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic complications in a patient with high-risk acute lymphoblastic leukemia and undiagnosed hereditary hemochromatosis.
Balagtas JM; Dahl GV
Pediatr Blood Cancer; 2012 Jan; 58(1):101-3. PubMed ID: 22076832
[TBL] [Abstract][Full Text] [Related]
26. Severe iron overload in Blackfan-Diamond anemia: a case-control study.
Roggero S; Quarello P; Vinciguerra T; Longo F; Piga A; Ramenghi U
Am J Hematol; 2009 Nov; 84(11):729-32. PubMed ID: 19810012
[TBL] [Abstract][Full Text] [Related]
27. An assessment of iron overload in children treated for cancer and nonmalignant hematologic disorders.
Rascon J; Rageliene L; Stankeviciene S; Palionis D; Tamosiunas AE; Valeviciene N; Zvirblis T
Eur J Pediatr; 2014 Sep; 173(9):1137-46. PubMed ID: 24659311
[TBL] [Abstract][Full Text] [Related]
28. Microarray analysis of liver gene expression in iron overloaded patients with sickle cell anemia and beta-thalassemia.
Flanagan JM; Steward S; Hankins JS; Howard TM; Neale G; Ware RE
Am J Hematol; 2009 Jun; 84(6):328-34. PubMed ID: 19384939
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease.
Kalpatthi R; Peters B; Kane I; Holloman D; Rackoff E; Disco D; Jackson S; Laver JH; Abboud MR
Pediatr Blood Cancer; 2010 Dec; 55(7):1338-42. PubMed ID: 20981690
[TBL] [Abstract][Full Text] [Related]
30. Retrospective review of pediatric patients with acute lymphoblastic leukemia: a single center experience.
Khalid S; Moiz B; Adil SN; Khurshid M
Indian J Pathol Microbiol; 2010; 53(4):704-10. PubMed ID: 21045397
[TBL] [Abstract][Full Text] [Related]
31. Clinical consequences of iron overload from chronic red blood cell transfusions, its diagnosis, and its management by chelation therapy.
Shander A; Sazama K
Transfusion; 2010 May; 50(5):1144-55. PubMed ID: 20088842
[TBL] [Abstract][Full Text] [Related]
32. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
[TBL] [Abstract][Full Text] [Related]
33. Iron overload in children who are treated for acute lymphoblastic leukemia estimated by liver siderosis and serum iron parameters.
Halonen P; Mattila J; Suominen P; Ruuska T; Salo MK; Mäkipernaa A
Pediatrics; 2003 Jan; 111(1):91-6. PubMed ID: 12509560
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the effects of different transfusion trigger levels during the treatment of childhood acute lymphoblastic leukemia.
Paananen P; Arola MO; Pelliniemi TT; Salmi TT; Lähteenmäki PM
J Pediatr Hematol Oncol; 2009 Oct; 31(10):745-9. PubMed ID: 19734805
[TBL] [Abstract][Full Text] [Related]
35. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome.
Ballerini P; Landman-Parker J; Cayuela JM; Asnafi V; Labopin M; Gandemer V; Perel Y; Michel G; Leblanc T; Schmitt C; Fasola S; Hagemejier A; Sigaux F; Auclerc MF; Douay L; Leverger G; Baruchel A
Haematologica; 2008 Nov; 93(11):1658-65. PubMed ID: 18835836
[TBL] [Abstract][Full Text] [Related]
36. Iron overload in children undergoing cancer treatments.
de Ville de Goyet M; Moniotte S; Robert A; Dupont S; Vermylen C; Veyckemans F; Brichard B
Pediatr Blood Cancer; 2013 Dec; 60(12):1982-7. PubMed ID: 23897631
[TBL] [Abstract][Full Text] [Related]
37. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy.
Leitch HA; Chase JM; Goodman TA; Ezzat H; Rollins MD; Wong DH; Badawi M; Leger CS; Ramadan KM; Barnett MJ; Foltz LM; Vickars LM
Hematol Oncol; 2010 Mar; 28(1):40-8. PubMed ID: 19557769
[TBL] [Abstract][Full Text] [Related]
38. Early Cardiac Iron Overload in a Child on Treatment of Acute Lymphoblastic Leukemia.
Reitman AJ; Coates TD; Freyer DR
Pediatrics; 2015 Sep; 136(3):e697-700. PubMed ID: 26283784
[TBL] [Abstract][Full Text] [Related]
39. No evidence of a trial effect in newly diagnosed pediatric acute lymphoblastic leukemia.
Koschmann C; Thomson B; Hawkins DS
Arch Pediatr Adolesc Med; 2010 Mar; 164(3):214-7. PubMed ID: 20194252
[TBL] [Abstract][Full Text] [Related]
40. Gaps in the diagnosis and management of iron overload in sickle cell disease: a 'real-world' report from the GRNDaD registry.
Wilson SR; Sears M; Williams E; Drapekin J; Sivakumar I; Padrino S; Desai PC; Hager W; Manwani D; Clay LJ; Field JJ; Kanter J; Cohen AJ; Saif Ur Rehman S; Lanzkron S; Little JA;
Br J Haematol; 2021 Dec; 195(5):e157-e160. PubMed ID: 34423416
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
